Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lava Therapeutics N.V.
(NQ:
LVTX
)
1.790
-0.030 (-1.65%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lava Therapeutics N.V.
< Previous
1
2
3
Next >
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
June 01, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space
October 25, 2022
Via
Benzinga
Why LAVA Therapeutics Stock Is Up More Than 100% Today
September 26, 2022
LAVA Therapeutics N.V.
Via
Benzinga
LAVA Announces Annual Meeting of Shareholders
May 30, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
April 11, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
March 09, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
February 16, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
February 09, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
February 06, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
January 23, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Appointment of New Directors to the Board
January 06, 2023
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
December 14, 2022
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
Via
Benzinga
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 16, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
November 03, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 03, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
November 01, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
October 25, 2022
Upgrades
Via
Benzinga
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
October 07, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
September 27, 2022
Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.
Via
Benzinga
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
September 27, 2022
Gainers
Via
Benzinga
Nasdaq Turns Lower; Crude Oil Drops Sharply
September 26, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite turning negative on Monday.
Via
Benzinga
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
September 26, 2022
Gainers
Via
Benzinga
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
September 26, 2022
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development
Via
Spotlight Growth
Dow Drops Over 100 Points; Crude Oil Rises Over 1%
September 26, 2022
U.S. stocks traded mixed midway through trading, with the Dow Jones dropping more than 100 points on Monday.
Via
Benzinga
What Is Going on With Lava Therapeutics (LVTX) Stock Today?
September 26, 2022
Lava Therapeutics (LVTX) stock is rocketing higher on Monday as investors react to an exclusive global license agreement with Seagen (SGEN).
Via
InvestorPlace
US Stocks Mostly Higher; Nasdaq Rises Over 100 Points
September 26, 2022
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.